Measles, also known as rubella, is caused by viral infection of measles virus that transfers through the respiratory route and causes systemic disease. Cough, fever, runny nose, rashes, and watery eyes (also known as conjunctivitis) are the symptoms observed in patients with measles. Two or three days after the occurrence of symptoms, tiny white spots (also known as kolpik spots) begins to appear in the oral cavity. Kolpik spots are flat red with small bumps. The person suffers from the fever of more than 104-degree Fahrenheit. Measles virus can be transferred from one person to another person through coughing and sneezing. The complications associated with measles are ear infections, pneumonia, encephalitis, and diarrhoea. Long term complications include a fatal central nervous system disorder, subacute sclerosing panencephalitis, which is very rare. Biological E Ltd. is in the process of developing measles rubella vaccine for the treatment of measles. Some of the companies having the pipeline of measles include Biological E Ltd., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.